Clerking, prescribing and admissions
Turn a referral into a safe inpatient plan.
What to expect
An OMFS admission needs a clear reason, baseline observations, medical and drug review, a provisional diagnosis and a management plan that another team can follow. DCTs commonly coordinate bloods, imaging, analgesia, IV access, fasting instructions, fluids and theatre communication, with senior review.
What to know
Record allergies with reaction, anticoagulant/antiplatelet indication, diabetes medicines, renal function, pregnancy possibility where relevant and recent intake. Reconcile medicines and use the current local formulary for dose and route. IV fluids require a reason and monitoring plan, considering maintenance, replacement and resuscitation separately. Assess VTE and bleeding risk under local policy. Document escalation status and who will review pending investigations.
A practical approach
Use a problem list: immediate risks, working diagnosis, investigations, analgesia, source control or operation, fluids/nutrition, observations, specialist input and discharge criteria. For a fasting fracture patient, contact theatre coordination and anaesthetics as directed by the registrar; do not assume “nil by mouth” alone is a complete plan. Handover delayed cases with revised fasting, analgesia and fluid review.
Safety point
Do not copy a standard prescription into a patient with renal impairment, allergy, anticoagulation or frailty. Ask the prescriber/medical team when competence or authority is uncertain.
Targeted laboratory tests and result interpretation
Request a test because its result could change care. Distinguish a screening result, a diagnostic clue and an urgent physiological abnormality.
Common investigations and the question behind them
| Investigation | Useful question | Interpretive limit |
|---|---|---|
| FBC | Anaemia, platelet count, neutropenia or other blood-cell abnormality | A total white count alone does not grade infection severity. |
| Renal function / electrolytes | Drug clearance, dehydration, renal disease and electrolyte risk | Use the relevant calculation / product advice; trends and patient factors matter. |
| Liver tests | Hepatocellular, cholestatic or synthetic concerns | Normal transaminases do not exclude every chronic liver problem. |
| Glucose / ketones | Acute metabolic risk | HbA1c is a different question about longer-term glycaemic exposure. |
| Haematinics | Selected recurrent ulceration / suspected deficiency | A deficiency does not explain every ulcer or remove a cancer concern. |
| Coagulation studies | Directed bleeding / medicine / systemic question | Routine screens do not detect all bleeding disorders or quantify every anticoagulant. |
Avoid false certainty
A reference interval describes a population distribution, not a boundary between health and disease for every individual. Mild abnormalities may be incidental; a “normal” result may be inappropriate for a sick patient or fail to measure the process of interest. Interpret timing, baseline, symptoms, medicines and the proposed procedure.
Test sensitivity and specificity do not remove the role of pre-test probability. Negative serology does not exclude every cause of salivary dysfunction or granulomatous disease. A mildly raised inflammatory marker cannot identify the source of infection. Persistent clinical red flags still require the appropriate investigation even when screening tests are reassuring.
Close the result loop
Specify who will review the result, the expected timescale and how the patient will be informed. Check missing or delayed results rather than assuming no news means normal. Record the interpretation and the action, including communication with the treating team where medical complexity changes the plan.
Acute deterioration is managed clinically while investigations proceed. A patient with a threatened airway, significant haemorrhage or possible sepsis requires immediate assessment and escalation. An outpatient blood-test request is not an adequate response to time-critical physiological compromise.
A useful test has a decision attached
Before testing
- State a clinical question
- Choose a relevant investigation
- Decide how results could change care
At interpretation
- Compare with context and baseline
- Consider limitations and timing
- Resolve discordant findings
After testing
- Review and communicate the result
- Record treatment / referral action
- Track outstanding or repeat tests
A distinction to remember
A test request without a named reviewer and action plan can create false reassurance. Normal screening results do not override a convincing serious clinical pattern.
Why might an FBC be useful before surgery in a patient recently treated with chemotherapy?
Reveal the reasoning
It can help establish blood-cell abnormalities such as neutropenia and thrombocytopenia, which affect infection and bleeding planning. Timing relative to treatment and liaison with the oncology team are essential; one old normal result is insufficient.
Dose calculations and prescribing governance
Carry units through every step. Concentration, volume, total dose and patient-specific limits are different quantities; a correct arithmetic result is not by itself a safe prescription.
Convert before multiplying
| Expression | Conversion | Worked quantity |
|---|---|---|
| 2% solution | 2 g / 100 mL = 20 mg/mL | 1.8 mL contains 36 mg; 2.2 mL contains 44 mg. |
| 4% solution | 4 g / 100 mL = 40 mg/mL | 1.8 mL contains 72 mg. |
| Adrenaline 1:100,000 | 1 g / 100,000 mL = 10 micrograms/mL | 1.8 mL contains 18 micrograms. |
| Adrenaline 1:80,000 | 1 g / 80,000 mL = 12.5 micrograms/mL | 2.2 mL contains 27.5 micrograms. |
| Adrenaline 1 mg/mL | 1,000 micrograms/mL | 0.5 mL contains 500 micrograms. |
Worked total-dose accounting
Three 2.2 mL cartridges of a 2% solution deliver 3 × 2.2 × 20 = 132 mg of the local anaesthetic. If that formulation contains adrenaline 1:80,000, the same volume delivers 3 × 2.2 × 12.5 = 82.5 micrograms of adrenaline. These calculations describe contents, not a recommendation that the dose is suitable for a particular patient.
To assess a limit, use the exact product and current reference, the patient factors and any relevant weight-based and absolute maxima. Account for all local-anaesthetic preparations already used. Cartridge volume varies; do not memorise “one cartridge equals one dose” without reading the formulation. Keep mg and micrograms distinct.
Make the prescription unambiguous
Use the correct patient, indication, generic medicine where appropriate, strength, dose, route, frequency and duration. Check allergy, interactions, contraindications and relevant organ function. Decimal and unit errors can be serious; write the amount so it cannot be mistaken and follow the local prescribing system.
Explain use, review and important adverse effects, document the decision and report appropriate suspected serious reactions through the MHRA Yellow Card scheme. A calculation that passes arithmetic checks still requires clinical verification of the medicine, formulation and patient-specific plan.
Concentration is not the final patient dose
Contents
- Convert % or ratio to mass per mL
- Multiply by actual volume
- Sum all doses already delivered
Suitability
- Check exact product and patient factors
- Apply current relevant limits
- Assess interacting or additive medicines
Communication
- Write dose, route, frequency and duration clearly
- Explain use and review
- Document and monitor the effect
Worked quantities are arithmetic examples. Product limits and the patient determine clinical suitability.
A distinction to remember
500 micrograms is 0.5 mg, not 500 mg. A 2% solution contains 20 mg/mL, not 2 mg/mL.
How much local anaesthetic is in two 1.8 mL cartridges of a 4% solution?
Reveal the reasoning
4% = 40 mg/mL. Total volume is 3.6 mL, so the amount is 3.6 × 40 = 144 mg. The calculation does not establish whether that amount is appropriate for the patient.
Guidance to read alongside this chapter
Test your recall
What distinguishes a safe IV fluid order from “give fluids”?
Show answer
The indication, type and rate per current guidance, patient-specific risks, monitoring and reassessment plan.
